9:00 AM ET
8-K
Court & Legal Update
Ultragenyx Pharmaceutical Court & Legal Update
Ultragenyx and Baylor Research Institute entered into a settlement agreement with Navinta LLC to resolve patent litigation regarding DOJOLVI® (triheptanoin). Under the agreement, Navinta is granted a non-exclusive, royalty-free license to market a generic version of the drug starting January 1, 2033, or July 1, 2033 if pediatric exclusivity is granted.
- Counterparty
- Navinta LLC